COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

Ventus and Genentech partner for small-molecule medicine discovery

Acquisition strengthens Aspire Pharma’s strategic portfolio

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies